CHICAGO, Aug. 7, 2015 /PRNewswire-USNewswire/ -- Northwestern Medicine® and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University are proud to announce the naming of the Lynn Sage Cancer Research Foundation (LSCRF) Breast Cancer OncoSET (Sequence, Evaluate, Treat) program. LSCRF Breast Cancer OncoSET will provide a more personalized, precision medicine treatment approach for breast cancer patients by combining oncology with genomic tumor profiling. The program will initially focus on patients with breast cancer that is non-responsive to traditional therapeutic treatments.
LSCRF Breast Cancer OncoSET is an extension of the Northwestern OncoSET program that was first launched in early 2015 by the Lurie Cancer Center, in collaboration with Northwestern Memorial Hospital. The Breast Cancer OncoSET program was made possible by a generous donation from the Lynn Sage Cancer Research Foundation, which is the first major naming gift that a Northwestern OncoSET program has received. This support will fund important research to develop new treatments based on the molecular abnormalities identified through the program.
"We are very excited and appreciative of the Lynn Sage Cancer Research Foundation's gift," said Leonidas Platanias, MD, PhD, director of the Lurie Cancer Center. "Their support of our vision will help establish Chicago as a leader in precision cancer care."
LSCRF Breast Cancer OncoSET will enable Lurie Cancer Center physicians to provide patients with the personalized treatment options or clinical trials that will benefit them most by sequencing the genetic profile of an individual patient's tumor – known as genomic profiling – and evaluating the results. Therapeutic approaches may include early-stage clinical trials, as well as site-agnostic, pathway-driven treatments targeting the genetic abnormalities of one type of cancer and using them to treat a different type of cancer if they share the same mutation.
By offering cancer patients care within LSCRF Breast Cancer OncoSET, the program is also expanding the Lurie Cancer Center's pre-clinical research by collecting and analyzing detailed data from each patient's genomic profile. The information collected will allow researchers to identify new treatment patterns and important genomic pathways to develop novel approaches to cancer treatment.
"The goal of the Lynn Sage Cancer Research Foundation is to provide patients with access to the latest technological and medical advances for treating breast cancer," said Ashley Netzky, chair of the LSCRF's board of directors. "It is very rewarding to know that this new OncoSET program will be able to do exactly that for breast cancer patients right here in Chicago using a precision medicine approach."
"The Lynn Sage Cancer Research Foundation Breast Cancer OncoSET program will not only allow us to expand the number of new treatment options available for patients, but also enhance our clinical trial offerings," said Francis Giles, MD, deputy director of the Lurie Cancer Center, and director of Northwestern Medicine Developmental Therapeutics Institute. "In addition, the program will allow us to learn more about which genomic targets are the most important in treating breast cancer and identify additional potential genetic targets for new drugs in the future."
To learn more about the cancer care at the Lurie Cancer Center or schedule an appointment, call 312-695-0990 or visit: cancer.northwestern.edu.
To learn more about Northwestern Medicine, please visit: http://news.nm.org/about-northwestern-medicine.html.
SOURCE Northwestern Memorial Hospital